Results 311 to 320 of about 1,226,593 (337)
Some of the next articles are maybe not open access.
Radiolabeled Monoclonal Antibodies
AORN Journal, 1995ABSTRACTMonoclonal antibodies (MoAbs) are biologically engineered proteins designed to bind to antigens emanating from tumor cells. Selected radioactive isotopes are fused with MoAbs to allow radioimmunodetection or external imaging of metastatic deposits in patients with colon cancer.
C L, Brumley, J A, Kuhn
openaire +2 more sources
2009
The ability to produce and exploit monoclonal antibodies (mAbs) has revolutionized many areas of biological sciences. The unique property of an mAb is that it is a single species of immunoglobulin (IG) molecule. This means that the specificity of the interaction of the paratopes on the IG, with the epitopes on an antigenic target, is the same on every ...
openaire +2 more sources
The ability to produce and exploit monoclonal antibodies (mAbs) has revolutionized many areas of biological sciences. The unique property of an mAb is that it is a single species of immunoglobulin (IG) molecule. This means that the specificity of the interaction of the paratopes on the IG, with the epitopes on an antigenic target, is the same on every ...
openaire +2 more sources
Monoclonal antibody technology
American Journal of Health-System Pharmacy, 1986The development, production, limitations, and uses of monoclonal antibody (MoAb) technology are presented. The first MoAbs were developed in 1975 using a process whereby the antibody-producing spleen cells of mice that had been immunized against sheep red blood cells were fused with the cells of a mouse myeloma cell line, producing hybridomas.
J A, Tami +3 more
openaire +2 more sources
Drug News & Perspectives, 2005
The success of molecular target-based cancer therapy exampled by Herceptin targeting Her2 indicates that cancer immunotherapy involves identifying and targeting key molecular drivers of cancer. Recently, the human Cripto, a founding member of the epidermal growth factor-Cripto-FRL1-Cryptic (EGF-CFC) protein family has been demonstrated to be a unique ...
Xiu Feng, Hu, Pei Xiang, Xing
openaire +2 more sources
The success of molecular target-based cancer therapy exampled by Herceptin targeting Her2 indicates that cancer immunotherapy involves identifying and targeting key molecular drivers of cancer. Recently, the human Cripto, a founding member of the epidermal growth factor-Cripto-FRL1-Cryptic (EGF-CFC) protein family has been demonstrated to be a unique ...
Xiu Feng, Hu, Pei Xiang, Xing
openaire +2 more sources
Recombinant Monoclonal Antibodies
2007Recombinant antibody technology is a rapidly evolving field that enables the study and improvement of antibody properties by means of genetic engineering. Moreover, the functional expression of antibody fragments in Escherichia coli has formed the basis for antibody library generation and selection, a powerful method to produce human antibodies for ...
Mariel, Donzeau, Achim, Knappik
openaire +2 more sources
Therapeutic monoclonal antibodies
The Lancet, 2000The therapeutic potential of monoclonal antibodies (mAb) was quickly realised after the hybridoma technique allowed their development in the mid 1970s. Chimeric humanised and fully humanised mAb can now be made by recombinant engineering. About a quarter of all biotech drugs in development are mAb, and around 30 products are in use or being ...
openaire +2 more sources
Radioiodinated monoclonal antibodies
International Journal of Biochemistry, 1988Antibodies were first described by Von Behring almost 100 years ago. Following their early use as putative therapeutic agents in the treatment of infectious and malignant disease (Hericourt and Richet, 1885) their clinical applications dwindled until, at the present day, passive immunotherapy is largely limited to the treatment of such conditions as ...
openaire +2 more sources
Engineering monoclonal antibodies
Nature, 1989Efforts to alter the mAb component of pharmaceuticals have focused on making them more human-lIke and smaller. Ultimately, the smallest molecular recognition unit derived from antibodies may be a single complementarity region.
openaire +2 more sources
Immunology Today, 1988
Abstract Reproducible and efficient production of human monoclonal antibodies of predefined specificity has proved to be a notoriously difficult task. Many variations on basic production techniques now exist and, as Keith Thompson reviews here, the comparative ease with which they can now be made promises to open up numerous new research avenues.
openaire +2 more sources
Abstract Reproducible and efficient production of human monoclonal antibodies of predefined specificity has proved to be a notoriously difficult task. Many variations on basic production techniques now exist and, as Keith Thompson reviews here, the comparative ease with which they can now be made promises to open up numerous new research avenues.
openaire +2 more sources